Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy – protocol of a multicentre, single arm phase 2 trial (SAKK 06/19)

INTRODUCTION: The combination of checkpoint inhibition and cisplatin-based chemotherapy is investigated in muscle invasive bladder cancer (MIBC) and results from phase 2 trials have been presented. Intravesical BCG has been used for non-MIBC (NMIBC) in patients with carcinoma in situ and high-grade...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrausch, Ulf, Spahn, Martin, Schneider, Martina, Hayoz, Stefanie, Rentsch, Cyrill A, Rothschild, Sacha, Omlin, Aurelius, Cathomas, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255003/
https://www.ncbi.nlm.nih.gov/pubmed/37286312
http://dx.doi.org/10.1136/bmjopen-2022-067634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255003/
https://www.ncbi.nlm.nih.gov/pubmed/37286312
http://dx.doi.org/10.1136/bmjopen-2022-067634

Ejemplares similares